InterMune's hepatitis strategy gets the right response
11 Feb 05
PharmiWeb Fri, 11 Feb 2005 5:18 AM PST
A significant rise in sales of InterMune's hepatitis drug Infergen, from $9.3 million in 2003 to $22.3 million in 2004, is the result of the company's focus on marketing Infergen to HCV non-responders. In targeting this vital patient sub-group, InterMune could gain a useful head start in an area of hepatitis treatment that is set to become fiercely competitive in the years ahead.
[Non-text portions of this message have been removed]